Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection
Chronic HBV infection (CHB) is a major contributor to liver-related deaths worldwide. The ultimate endpoint of CHB treatment is sustained HBV surface antigen (HBsAg) loss.
Here, we report the design of a series of HBV surface antigen inhibitors which promotes reduction of HBV antigens in vitro and in vivo.
https://pubmed.ncbi.nlm.nih.gov/36089112/
Related Content
STAT proteins are key mediators of cellular immunity, proliferation, apoptosis, and differentiation. STATs are known to play a role in...
VIEW RESOURCEAt the Covalent Drug Discovery 2023 Summit and Fragments 2024 Conference, we presented a case study on Bruton’s tyrosine kinase (BTK)...
VIEW RESOURCE